SANTA CRUZ BIOTECHNOLOGY, INC.

EG-VEGF (hBA-86): sc-4849



BACKGROUND

Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) induces proliferation, migration and fenestration in capillary endothelial cells derived from endocrine glands. EG-VEGF possesses a HIF-1 binding site; its expression is induced by hypoxia and restricted to the steroidogenic glands (ovary, testis, adrenal and placenta). EG-VEGF expression is often complementary to the expression of VEGF, suggesting that these molecules function in a coordinated manner. EG-VEGF is an example of a class of highly specific mitogens that act to regulate proliferation and differentiation of the vascular endothelium in a tissue-specific manner. EG-VEGF is expressed largely in one type of tissue and acts selectively on one type of endothelium. EG-VEGF, possibly through binding to a G protein-coupled receptor, results in the activation of MAPK p44/42 and phosphatidylinositol 3-kinase signaling pathways, leading to proliferation, migration and survival of responsive endothelial cells.

REFERENCES

- Carmeliet, P. 2001. Cardiovascular biology. Creating unique blood vessels. Nature 412: 868-869.
- 2. LeCouter, J., et al. 2001. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 412: 877-984.
- Lin, R., et al. 2002. Characterization of endocrine gland-derived vascular endothelial growth factor signaling in adrenal cortex capillary endothelial cells. J. Biol. Chem. 277: 8724-8729.
- Lin, D.C., et al. 2002. Identification and molecular characterization of two closely related G protein-coupled receptors activated by prokineticins/EG-VEGF. J. Biol. Chem. 277: 19276-19280.
- Ferrara, N., et al. 2002. Endocrine gland vascular endothelial growth factor (EG-VEGF) and the hypothesis of tissue-specific regulation of angiogenesis. Endocr. Res. 28: 763-764.
- Masuda, Y., et al. 2002. Isolation and identification of EG-VEGF/prokineticins as cognate ligands for two orphan G protein-coupled receptors. Biochem. Biophys. Res. Commun. 293: 396-402.
- Lecouter, J., et al. 2004. EG-VEGF: a novel mediator of endocrine-specific angiogenesis, endothelial phenotype and function. Ann. N.Y. Acad. Sci. 1014: 50-57.

CHROMOSOMAL LOCATION

Genetic locus: PROK1 (human) mapping to 1p21; Prok1 (mouse) mapping to 3 F2.3.

SOURCE

EG-VEGF (hBA-86) is produced in *E. coli* as 9.6 kDa biologically active protein corresponding to 86 amino acids of EG-VEGF of human origin.

PRODUCT

EG-VEGF (hBA-86) is purified from bacterial lysates (>98%); supplied as 10 μg purified protein.

RECONSTITUTION

In order to avoid freeze/thaw damaging of the active protein, dilute protein when first used to desired working concentration. Either a sterile filtered standard buffer (such as 50mM TRIS or 1X PBS) or water can be used for the dilution. Store any thawed aliquot in refrigeration at 2° C to 8° C for up to four weeks, and any frozen aliquot at -20° C to -80° C for up to one year. It is recommended that frozen aliquots be given an amount of standard cryopreservative (such as Ethylene Glycol or Glycerol 5-20% v/v), and refrigerated samples be given an amount of carrier protein (such as heat inactivated FBS or BSA to 0.1% v/v) or non-ionic detergent (such as Triton X-100 or Tween 20 to 0.005% v/v), to aid stability during storage.

STORAGE

Store desiccated at -20° C; stable for one year from the date of shipment.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.